CGEM - Cullinan Oncology, Inc.
IEX Last Trade
11.97
0.060 0.501%
Share volume: 6,804
Last Updated: Fri 27 Dec 2024 08:30:05 PM CET
Research and Development in Biotechnology (except Nanobiotechnology):
0.25%
PREVIOUS CLOSE
CHG
CHG%
$11.91
0.06
0.50%
Fundamental analysis
4%
Profitability
0%
Dept financing
0%
Liquidity
0%
Performance
10%
Performance
5 Days
8.68%
1 Month
-1.45%
3 Months
-24.96%
6 Months
-24.52%
1 Year
28.36%
2 Year
32.72%
Key data
Stock price
$11.97
DAY RANGE
$11.88 - $12.76
52 WEEK RANGE
$10.44 - $30.19
52 WEEK CHANGE
$26.59
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
11/06/2024
Company detail
CEO: Nadim Ahmed
Region: US
Website: cullinanoncology.com
Employees: 30
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Region: US
Website: cullinanoncology.com
Employees: 30
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Cullinan Oncology Inc. focuses on developing a pipeline of targeted oncology and immuno-oncology therapies for cancer patients in the United States. The company's lead candidate is the CLN-081, an orally available small molecule that is in a Phase I/IIa dose escalation and expansion trial for treating patients with non-small cell lung cancer.
Recent news